Skip to main
ALT

Altimmune (ALT) Stock Forecast & Price Target

Altimmune (ALT) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Altimmune is a late clinical-stage biopharmaceutical company with a strong candidate in pemvidutide targeting serious liver diseases including MASH, AUD, and ALD, with additional indications in the pipeline. With Phase 3 PERFORMA trial initiation expected in 2026 and Ph2 RECLAIM and RESTORE trials providing de-risking catalysts, Altimmune's differentiated clinical profile and 75% probability of success for pemvidutide in MASH could lead to peak sales of $3B worldwide. Additionally, the company's strong financial position with pro-forma cash of $340M and strategic partnerships, along with its novel AI-assisted decision-support tool, could reduce inter-reader variability and expedite timelines for drug development. While there are clinical and financial risks associated with NASH development, Altimmune remains well-positioned in the third wave of candidates seeking FDA and EMEA approval in the 2026+ timeframe.

Bears say

Altimmune is a clinical-stage biopharmaceutical company with promising drug candidate pemvidutide targeting multiple serious liver diseases and expanding into AUD and ALD indications, but its early development stage, crowded competitive landscape, and uncertainty about the commercial market for these indications present major risks for the company. The recent financing deals and strong balance sheet are positive indicators, but the lack of proof-of-concept data and future capital requirements also need to be closely monitored.

Altimmune (ALT) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Altimmune (ALT) Forecast

Analysts have given Altimmune (ALT) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Altimmune (ALT) has a Strong Buy consensus rating as of May 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Altimmune (ALT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.